Corporate
News release
TopTOKYO, JAPAN - February 26, 2019 - Terumo Corporation (TSE: 4543) today announced that it plans to construct a new building to house its third manufacturing facility in Vietnam. It expects construction to be completed in December 2020. The Company will also install additional production facilities to increase production at the current first and second buildings. The investment will total approximately 15 billion yen over 5 years, and as a result of this investment, production capacity is expected to double.
The Vietnamese factory, which started its operation in 2008, mainly produces products for interventional therapeutics, which it ships to: Europe, South America, and Asia - including China and India. The interventional therapeutics market is anticipated to grow rapidly especially in China and India, and Terumo intends to develop a production system that can meet demands in those regions.
Terumo has made "Strengthen Global Operations" as one of its key initiatives in carrying out its Mid- to Long-term Growth Strategy, and is therefore reinforcing production capacity and optimizing global production. In the interventional therapeutics field, the Company has strengthened its production system by developing production sites in: Shizuoka, Yamaguchi, and Gifu prefectures in Japan; and in the US, Belgium, Puerto Rico, Vietnam, and China globally.
As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world - by consistently providing "Total Quality": highest quality in all product, supply, and service.
About Terumo
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 30,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.